A new approach to treating inherited sight loss
A new approach to treating inherited sight loss
Search
Search results
First clinical trial participant receives CRISPR-based therapy
An American living with Leber congenital amaurosis 10 (LCA10) has become the first clinical trial participant in the world to receive a CRISPR gene editing treatment in vivo (inside the body).
ProQR announces agreement with Laboratoires Théa for inherited retinal disease programmes
Biotechnology company ProQR has announced that two of its RNA therapy development programmes for inherited sight loss are being acquired by Laboratoires Théa, a company specialising in eye care products.
Eye2Gene: predicting genetic diagnosis from eye scans
Eye2Gene: new publication describes how AI can predict genetic diagnosis from retinal scans
e-Newsletter April 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
e-Newsletter May 2025
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Webinar: How your donations make a difference…in conversation with our new research grantees
Join Research Development Manager, Kate Arkell as she speaks to our latest research grantees about their projects.
SparingVision completes dosing in PRODYGY trial of SPVNO6 for retinitis pigmentosa.
SparingVision have announced this week that they have dosed all participants in their phase 1/2 PRODYGY clinical trial for SPVN06, a gene agnostic therapy aimed at slowing disease progression in Retinitis Pigmentosa (RP).
e-Newsletter December 2025
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Look Forward – Winter 2023 – Issue 181
Inside this edition, register now for our AI webinar on 7 December with Dr Nikolas Pontikos.